Tier 3 — preclinical

Unravelling the bioavailability of amino acids and bioactive peptides from collagen hydrolysate in coffee in healthy volunteers

Nicolina Virgilio, Christiane Schoen, Bastiaan van der Steen, Anne J. Kleinnijenhuis, Frédérique L. van Holthoon, Sara Vleminckx, Catarina I. F. Silva, Janne Prawitt
Food Research International 2025 211:116478

Bibliography

PubMed
PMID 40356137
DOI
10.1016/j.foodres.2025.116478
Funding
A specific funding statement was not available in the accessible PubMed/abstract record reviewed. Several authors were employees of Rousselot BV, the collagen manufacturer; this relationship is recorded under competing interests.
Competing interests
Virgilio, van der Steen, Vleminckx, Silva and Prawitt reported employment by Rousselot BV; other authors reported no known competing financial interests or personal relationships.

Study snapshot

DesignRandomized crossover single-dose human bioavailability study
ModelHealthy adult volunteers
SampleThe published PubMed and publisher abstracts do not report the sample size.
InterventionSingle fasting dose of bovine collagen hydrolysate dissolved in water versus coffee in a randomized crossover design; the published abstract does not report the dose.
Duration360-minute post-dose pharmacokinetic sampling
EndpointsPlasma hydroxyproline; Plasma glycine; Plasma proline; Pro-Hyp; Hyp-Gly; Gly-Pro-Hyp; iAUC; Cmax; Tmax

What the study showed, in plain terms

This randomized crossover study tested whether mixing bovine collagen hydrolysate into coffee changed absorption compared with water. Coffee altered some free-amino-acid kinetics, but the key measured collagen-derived peptides showed similar pharmacokinetic exposure in coffee and water.

Key findings

Free hydroxyproline and proline showed differences in post-dose plasma profiles between coffee and water. For measured bioactive peptides, iAUC, Cmax and Tmax were reported as similar between the two matrices.

What this study can and cannot tell us

This was a single-dose pharmacokinetic study with no clinical skin, joint, bone or muscle outcomes. Multiple authors were employees of Rousselot, the collagen manufacturer. The published abstracts do not report sample size or the collagen dose, so this record does not infer those values.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology